Current and future targets for faecal microbiota transplantation

James Roger Mcilroy, Jonathan P. Segal, Benjamin H. Mullish, Mohammed Nabil Quraishi, Antonio Gasbarrini, Giovanni Cammarota, Gianluca Ianiro

Research output: Contribution to journalArticle

Abstract

The human gastrointestinal tract is home to the most diverse microbial ecosystem in the human body and is made up of bacteria, viruses and eukarya. Collectively known as the gut microbiota, our knowledge of these microbial communities has historically been restricted by the relative limitations of culturing techniques. However, the recent development and utilisation of next-generation sequencing techniques has enhanced our understanding of its structure, diversity and function. There is emerging evidence that the gut microbiota plays a pivotal role in both health and disease. Perturbations to the structure and function of the gut microbiota are known to be associated with certain disease states. Therefore, manipulating the gut microbiota in an attempt to restore structure and function represents a promising therapeutic strategy. Recently, there has been a surge in clinical and scientific interest in manipulating the gut microbiota using a method called faecal microbiota transplantation. This increase in interest has gathered after it was shown in randomised controlled trials to be highly effective in treating recurrent Clostridium difficile infection. Despite success in treating recurrent Clostridium difficile, there remain many unknowns about how best to optimise its preparation, regulation, mode of delivery and safety. This review aims to summarise the literature surrounding the current knowledge regarding faecal microbiota transplantation and explore potential future research avenues that aim to enhance the safety, efficacy and utilisation of faecal microbiota transplantation.

Original languageEnglish
JournalHuman Microbiome Journal
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Clostridium difficile
Clostridium Infections
Safety
Eukaryota
Human Body
Ecosystem
Gastrointestinal Tract
Randomized Controlled Trials
Gastrointestinal Microbiome
Fecal Microbiota Transplantation
Viruses
Bacteria
Health
Therapeutics

Keywords

  • Bacteriotherapy
  • Faecal microbiota transplantation
  • FMT
  • Microbiome
  • Microbiota

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Current and future targets for faecal microbiota transplantation. / Mcilroy, James Roger; Segal, Jonathan P.; Mullish, Benjamin H.; Nabil Quraishi, Mohammed; Gasbarrini, Antonio; Cammarota, Giovanni; Ianiro, Gianluca.

In: Human Microbiome Journal, 01.01.2018.

Research output: Contribution to journalArticle

Mcilroy, James Roger ; Segal, Jonathan P. ; Mullish, Benjamin H. ; Nabil Quraishi, Mohammed ; Gasbarrini, Antonio ; Cammarota, Giovanni ; Ianiro, Gianluca. / Current and future targets for faecal microbiota transplantation. In: Human Microbiome Journal. 2018.
@article{128763b3cbc8450cb8e972b63bd5872d,
title = "Current and future targets for faecal microbiota transplantation",
abstract = "The human gastrointestinal tract is home to the most diverse microbial ecosystem in the human body and is made up of bacteria, viruses and eukarya. Collectively known as the gut microbiota, our knowledge of these microbial communities has historically been restricted by the relative limitations of culturing techniques. However, the recent development and utilisation of next-generation sequencing techniques has enhanced our understanding of its structure, diversity and function. There is emerging evidence that the gut microbiota plays a pivotal role in both health and disease. Perturbations to the structure and function of the gut microbiota are known to be associated with certain disease states. Therefore, manipulating the gut microbiota in an attempt to restore structure and function represents a promising therapeutic strategy. Recently, there has been a surge in clinical and scientific interest in manipulating the gut microbiota using a method called faecal microbiota transplantation. This increase in interest has gathered after it was shown in randomised controlled trials to be highly effective in treating recurrent Clostridium difficile infection. Despite success in treating recurrent Clostridium difficile, there remain many unknowns about how best to optimise its preparation, regulation, mode of delivery and safety. This review aims to summarise the literature surrounding the current knowledge regarding faecal microbiota transplantation and explore potential future research avenues that aim to enhance the safety, efficacy and utilisation of faecal microbiota transplantation.",
keywords = "Bacteriotherapy, Faecal microbiota transplantation, FMT, Microbiome, Microbiota",
author = "Mcilroy, {James Roger} and Segal, {Jonathan P.} and Mullish, {Benjamin H.} and {Nabil Quraishi}, Mohammed and Antonio Gasbarrini and Giovanni Cammarota and Gianluca Ianiro",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.humic.2018.08.004",
language = "English",
journal = "Human Microbiome Journal",
issn = "2452-2317",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Current and future targets for faecal microbiota transplantation

AU - Mcilroy, James Roger

AU - Segal, Jonathan P.

AU - Mullish, Benjamin H.

AU - Nabil Quraishi, Mohammed

AU - Gasbarrini, Antonio

AU - Cammarota, Giovanni

AU - Ianiro, Gianluca

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The human gastrointestinal tract is home to the most diverse microbial ecosystem in the human body and is made up of bacteria, viruses and eukarya. Collectively known as the gut microbiota, our knowledge of these microbial communities has historically been restricted by the relative limitations of culturing techniques. However, the recent development and utilisation of next-generation sequencing techniques has enhanced our understanding of its structure, diversity and function. There is emerging evidence that the gut microbiota plays a pivotal role in both health and disease. Perturbations to the structure and function of the gut microbiota are known to be associated with certain disease states. Therefore, manipulating the gut microbiota in an attempt to restore structure and function represents a promising therapeutic strategy. Recently, there has been a surge in clinical and scientific interest in manipulating the gut microbiota using a method called faecal microbiota transplantation. This increase in interest has gathered after it was shown in randomised controlled trials to be highly effective in treating recurrent Clostridium difficile infection. Despite success in treating recurrent Clostridium difficile, there remain many unknowns about how best to optimise its preparation, regulation, mode of delivery and safety. This review aims to summarise the literature surrounding the current knowledge regarding faecal microbiota transplantation and explore potential future research avenues that aim to enhance the safety, efficacy and utilisation of faecal microbiota transplantation.

AB - The human gastrointestinal tract is home to the most diverse microbial ecosystem in the human body and is made up of bacteria, viruses and eukarya. Collectively known as the gut microbiota, our knowledge of these microbial communities has historically been restricted by the relative limitations of culturing techniques. However, the recent development and utilisation of next-generation sequencing techniques has enhanced our understanding of its structure, diversity and function. There is emerging evidence that the gut microbiota plays a pivotal role in both health and disease. Perturbations to the structure and function of the gut microbiota are known to be associated with certain disease states. Therefore, manipulating the gut microbiota in an attempt to restore structure and function represents a promising therapeutic strategy. Recently, there has been a surge in clinical and scientific interest in manipulating the gut microbiota using a method called faecal microbiota transplantation. This increase in interest has gathered after it was shown in randomised controlled trials to be highly effective in treating recurrent Clostridium difficile infection. Despite success in treating recurrent Clostridium difficile, there remain many unknowns about how best to optimise its preparation, regulation, mode of delivery and safety. This review aims to summarise the literature surrounding the current knowledge regarding faecal microbiota transplantation and explore potential future research avenues that aim to enhance the safety, efficacy and utilisation of faecal microbiota transplantation.

KW - Bacteriotherapy

KW - Faecal microbiota transplantation

KW - FMT

KW - Microbiome

KW - Microbiota

UR - http://www.scopus.com/inward/record.url?scp=85058207606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058207606&partnerID=8YFLogxK

U2 - 10.1016/j.humic.2018.08.004

DO - 10.1016/j.humic.2018.08.004

M3 - Article

AN - SCOPUS:85058207606

JO - Human Microbiome Journal

JF - Human Microbiome Journal

SN - 2452-2317

ER -